We believe patients deserve the best and that’s why we offer SpaceOAR® Hydrogel as part of our standard pre-radiotherapy treatment.
We design our care to help give patients the best possible life outcomes. Which is why since January 2018 we’ve successfully delivered 200 SpaceOAR® Hydrogel insertions as part of our standard pre radiotherapy treatment for men with prostate cancer, at no extra cost.
We offer a choice of 14 insertions sites in the UK with a further 10 in progress and 21 consultants available to deliver treatment.
What are the benefits of SpaceOAR® Hydrogel?
In a randomised clinical trial, at a median three-year follow-up, SpaceOAR® Hydrogel patients experienced reduced side-effects from prostate cancer radiation, including:
- 67% maintained sexual potency 3***
- A reduction in erectile disfunction (for men potent at baseline) 3
- 73% relative reduction in rectal v701*
- A reduction in bowel dysfunction1
- 66% fewer clinically significant declines in urinary QOL 2**
- A reduction in urinary incontinence2
- 0% Late Grade 2 or higher rectal toxicity 2
- A reduction in rectal toxicity from radiation exposure1
- An overall improvement in quality of life, compared to patients who did not receive the implant.1
For more information or to find out how to refer a patient contact us at your local GenesisCare centre.
1 Mariados, N. et al. 2015. Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology biology physics. 92(5), pp. 971 – 977.
2 Hamstra, D. et al. 2017. Continued Benefit to Rectal Separation for Prostate Radiation Therapy: Final Results of a Phase III Trial Hamstra, Daniel A et al International Journal of Radiation Oncology. Practical Radiation Oncology. 97(5), pp. 976 – 985.
3 Hamstra, D. et al. 2018. Sexual quality of life following prostate intensity modulated radiation therapy (IMRT) with a rectal/prostate spacer: Secondary analysis of a phase 3 trial. Practical Radiation Oncology. 8(1), pp. 7 – 15.
* average reduction when comparing pre and post-spacer treatment plans.
** defined as 2x the minimally important difference compared to control patients.
*** compared to 38% in the control group; of men who had erections sufficient for intercourse at baseline; median 3 years